Dipeptidyl Peptidase-4 Inhibitors as a Third-Line Oral Antihyperglycaemic Agent in Patients with Type 2 Diabetes Mellitus: The Impact of Ethnicity

Table 2

Changes in HbA1c: pre- versus posttriple therapy.

Subgroups	Mean change in HbA1c from baseline (%)	Test statistics
Baseline HbA1c
<8% ()	−0.64	;
8-9% ()	−1.12
>9% ()	−2.10
Obesity*
No ()	−1.18	;
Yes ()	−0.96
Age
<65 years ()	−1.25	;
≥65 years ()	−0.82
Gender
Male ()	−1.05	;
Female ()	−1.15
Diabetes duration
<10 years ()	−1.18	;
10–20 years ()	−1.00
>20 years ()	−1.20
Duration on triple therapy
<6 months ()	−1.19	;
≥6 months ()	−0.85

*Obese in Asians: BMI ≥ 28 kg/m²; obese in non-Asians: BMI ≥ 30 kg/m².